Cardiovascular diseases (CVDs) remain the leading cause of global mortality and disease burden, with a growing cohort of patients presenting with acute coronary syndrome despite lacking standard modifiable risk factors. This persistent residual risk dictates a shift toward more accurate biomarkers. Historically, lipid management has centered on LDL-C, a measure of cholesterol mass. However, LDL-C fails to account for particle heterogeneity, which is critical since the number of atherogenic apolipoprotein-B (apoB) containing particles, not their cholesterol mass, seems to drive plaque retention. This mini review scopes the contemporary evidence supporting the utility of apoB as a superior metric for risk stratification and therapeutic targeting. Evidence from Mendelian Randomization (MR) studies suggests a causal association between apoB and CVD risk. Furthermore, both observational and discordance analyses demonstrate that apoB, by representing a direct count of all circulating atherogenic particles, is a more accurate predictor of CVD risk than traditional markers like LDL-C and non-HDL-C, suggesting its superiority for identifying high-risk individuals. Despite its established analytical advantages, apoB testing remains vastly underutilized in routine clinical practice, often downgraded to a secondary status in global guidelines. Implementation is significantly hampered by the lack of universal assay harmonization and historical health insurance payment policies that categorize the test as optional. As evidence increasingly identifies apoB as a superior predictor of cardiovascular risk compared to LDL-C and non-HDL-C, its adoption as a high-value alternative target warrants serious consideration.
Sofia-Panagiota Giannakopoulou (Mon,) studied this question.